A prime example of this phenomenon is B cell acute lymphoblastic leukemia (B-ALL) acquiring resistance to chimeric antigen receptor-armed autologous T cells (CART-19), which are engineered to target the CD19 surface antigen of B cells [1]. Here, CD19 is linked to acute lymphoblastic leukemia.